DEXIS announced US Food and Drug Administration (FDA) 510(k) clearance for its artificial intelligence (AI)-powered dental imaging software.
DTX Studio Clinic integrates on-site imaging software and can indicate six types of dental pathologies.
DTX Studio Clinic highlights suspected areas of pathology on dental radiographs from periapical and bitewing intraoral images. The AI-powered software is a supporting diagnostic tool that helps identify caries, discrepancies at the margin, root canal defects, periapical radiolucency, bone loss, and calculus in dental patients.
DTX Studio Clinic is from Envista, a family of dental brands such as Nobel Biocare, Kerr and DEXIS. The clearance for DEXIS’s latest software adds to FDA backing for Envista’s AI-assisted mandibular nerve tracing in March 2022.
AI is becoming an increasingly permanent fixture in healthcare as the industry moves to free up clinician time and reduce costs. The AI market in healthcare was worth $1.5bn in 2019, according to GlobalData, and is expected to greatly exceed that valuation in the coming years.
According to a GlobalData analysis on medical device patents, Envista has one of the leading AI surgical planning application diversities. The clearance for dental pathology identification adds to the AI-powered features of the DTX Studio suite which, according to the company, is used by over 10,000 dental offices.
Envista CEO Amir Aghdaei said: “DEXIS is empowering practices to embrace digital dentistry for improved efficiencies and predictable patient outcomes.
“With our newest release of DTX Studio Clinic, featuring enhanced built-in AI features like the pathological dental findings, practices now have an enhanced solution for their digital workflow — from diagnosis to treatment planning to delivery of care.”